Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  1. Pubblicazioni

Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial.

Articolo
Data di Pubblicazione:
2023
Citazione:
Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial / Van Der Lei, S., Dijkstra, M., Nieuwenhuizen, S., Schulz, H.h., Vos, D., Versteeg, K.s., Buffart, T.e., Swijnenburg, R.j., De Vries, J., Bruynzeel, A., Van Den Tol, M.p., De Cobelli, F., Scheffer, H.j., Puijk, R.s., Haasbeek, C., Meijerink, M.r., And Collision Trial, G.. - In: CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY. - ISSN 0174-1551. - 46:8(2023), pp. 1076-1085. [10.1007/s00270-023-03498-8]
Abstract:
Background: Although microwave ablation (MWA) has a low complication rate and good efficacy for small-size (≤ 3 cm) colorectal liver metastases (CRLM), local control decreases with increasing size. Stereotactic body radiotherapy (SBRT) is gaining interest as a potential means to treat intermediate-size CRLM and might be less susceptible to increasing volume. The objective of this study is to compare the efficacy of MWA to SBRT in patients with unresectable, intermediate-size (3–5 cm) CRLM. Methods: In this two-arm, multicentre phase II/ III randomized controlled trial, 68 patients with 1–3 unresectable, intermediate-size CRLM suitable for both MWA and SBRT, will be included. Patients will be treated with MWA or SBRT as randomised. The Primary endpoint is local tumour progression-free survival (LTPFS) at 1 year (intention-to-treat analysis). Main secondary endpoints are overall survival, overall and distant progression-free survival (DPFS), local control (LC) and procedural morbidity and mortality and assessment of pain and quality of life. Discussion: Current guidelines lack clear recommendations for the local treatment of liver only intermediate-size, unresectable CRLM and studies comparing curative intent SBRT and thermal ablation are scarce. Although safety and feasibility to eradicate tumours ≤ 5 cm have been established, both techniques suffer from lower LTPFS and LC rates for larger-size tumours. For the treatment of unresectable intermediate-size CRLM clinical equipoise has been reached. We have designed a two-armed phase II/ III randomized controlled trial directly comparing SBRT to MWA for unresectable CRLM 3–5 cm. Level of Evidence : Level 1, phase II/ III Randomized controlled trial. Trial Registration: NCT04081168, September 9th 2019. Graphical Abstract: [Figure not available: see fulltext.]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Van Der Lei, S; Dijkstra, M; Nieuwenhuizen, S; Schulz, Hh; Vos, Djw; Versteeg, Ks; Buffart, Te; Swijnenburg, Rj; De Vries, Jjj; Bruynzeel, Ame; Van Den Tol, Mp; De Cobelli, Francesco; Scheffer, Hj; Puijk, Rs; Haasbeek, Cja; Meijerink, Mr; And Collision Trial, Group
Autori di Ateneo:
DE COBELLI FRANCESCO
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/156096
Link al Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/156096/205876/s00270-023-03498-8.pdf
Pubblicato in:
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
Journal
  • Dati Generali

Dati Generali

URL

https://link.springer.com/article/10.1007/s00270-023-03498-8
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.2.0